2nd Quarter - Report

JUUL LABS, INC. for JUUL LABS INC

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
—
Expenses
$640,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
2nd Quarter - Report (this page) Jul 21, 2025 $640,000 Replaced
2nd Quarter - Amendment Oct 20, 2025 $750,000 Yes

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Budget/Appropriations BUD

H.R.__/S.4690, Agriculture, Rural Development, FDA, and related Agencies Appropriations Act, FY 2025; provisions related to the regulation of tobacco and electronic nicotine delivery systems products, including enforcement against illicit products. H.R.__/S.__, Commerce, Justice, Science, and Related Agencies Appropriations Act, FY 2025; provisions related to the regulation of tobacco and electronic nicotine delivery system products, including enforcement against illicit products.

LobbyistCovered position, as disclosed
EMILY GOUGELET New —
MARY-SUMPTER LAPINSKI —

Contacted: Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 4690 (119th)

Tobacco TOB

-Risk-proportionate regulation for electronic delivery system products to advance tobacco harm reduction for adult smokers and policies to combat underage use. Issues related to enforcement of illicit tobacco products, including importation of counterfeit products. Issues related to taxation and user fees for tobacco and electronic nicotine delivery system products. Discussions related to implementation of Public Law 111-31, the Family Smoking Prevention and Tobacco Control Act, and PMTA submissions for deemed tobacco products.

LobbyistCovered position, as disclosed
EMILY GOUGELET New —
MARY-SUMPTER LAPINSKI —
JASON ROBINSON —

Contacted: Food & Drug Administration (FDA); SENATE; Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.